0001193125-26-096477.txt : 20260306 0001193125-26-096477.hdr.sgml : 20260306 20260306160356 ACCESSION NUMBER: 0001193125-26-096477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260304 FILED AS OF DATE: 20260306 DATE AS OF CHANGE: 20260306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Savage Brian CENTRAL INDEX KEY: 0002112339 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 26730816 MAIL ADDRESS: STREET 1: 400 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV PROVINCE COUNTRY: L3 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV PROVINCE COUNTRY: L3 4 1 ownership.xml 4 X0508 4 2026-03-04 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0002112339 Savage Brian C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A STREET TEL AVIV L3 6944020 ISRAEL false true false false Interim Chief Legal Officer false Ordinary Shares 2026-03-04 4 M false 4744 A 7670 D Ordinary Shares 2026-03-04 4 S false 1489 32.4645 D 6181 D Ordinary Shares 2026-03-04 4 M false 3466 A 9647 D Ordinary Shares 2026-03-04 4 S false 1186 32.4645 D 8461 D Restricted Share Units 2026-03-04 4 M false 4744 0 D Ordinary Shares 4744 0 D Restricted Share Units 2026-03-04 4 M false 3766 0 D Ordinary Shares 3766 7534 D Restricted Share Units 2026-03-04 4 A false 11280 0 A Ordinary Shares 11280 11280 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026. Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028. Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. /s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage 2026-03-06